Additional Patent Protection For Exoskeleton Focal-Force Angioplasty Platform Granted by the U.S. Patent Office

Transit Scientific achieved increased U.S. patent protection for their novel exoskeleton focal-force angioplasty technology using standard off-the-shelf peripheral transluminal angioplasty (PTA) balloons.

Park City, Utah USA, August 15, 2022. Transit Scientific, a Utah-based medical device company, today announced additional U.S. patent protection has been issued from the United States Patent and Trademark Office (USPTO) for its XO exoskeleton sheath platform.

Traditional PTA cutting, scoring, and constraining structure (CS) technologies are manufactured with metal or polymer wires, struts, blades, or grooves wrapped around, or fused to, the outside of the angioplasty balloon. These wires, struts, blades, and/or grooves expand with the balloon to provide focal force in calcified, hyperplastic, and/or resistant lesions to prevent dissection, dilate resistant lesions, and/or prep the vessel for other interventions. Traditional systems are bulky, difficult to use, cost-prohibitive, and require significant inventory.

The XO Score is a thin one-piece metal alloy exoskeleton sheath with up to 22 struts/grooves that slides over off-the-shelf angioplasty balloons in a hospital’s existing inventory. When the angioplasty balloon is inflated, the struts/grooves expand with the balloon and rotate 900 to apply focal force to the vessel. When the balloon is deflated, the XO struts/grooves rotate 900 back to an atraumatic position and the XO structure assists in balloon rewrap for removal.

XO’s technology is also designed to constrain balloons and prevent torsional and longitudinal shear during angioplasty balloon inflation.

“This additional patent protection for our novel XO technology helps support our continued innovation with this product platform,” said Greg Method, President & CEO of Transit Scientific. “We are motivated to expand the impact of this cutting-edge technology to help improve treatment options for CLI (critical limb ischemia), limb salvage, chronic dialysis fistula, and graft patients, and beyond.”

The XO Score has been safely used in hospital and office-based labs. It has been associated with successful dilatation of calcified lesions, angioplasty resistant lesions, and hemodialysis lesions at low pressures as a 1st use technology and/or when other systems fail. The XO design lets physicians select the PTA balloon platform of their choice to improve procedure flexibility, reduce inventory, and reduce procedural costs.

The XO Score system is FDA and CE-Mark cleared to dilate stenotic material in iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.

Transit Scientific is a private company that designs, develops, and commercializes medical devices including the FDA-cleared and CE Mark-cleared XO ScoreÒ and XO CrossÒ platforms plus the XO Cath Interventional Oncology and XO CS Coronary System under development. Transit Scientific has 20+ combined issued and pending U.S. and global patents.

www.XOScore.com

Transit Scientific Media contact: Kelly Himle - info@XOScore.com.